About These References
The information presented on Olaparib150mg.com is intended to provide general educational information about olaparib, including its uses, mechanism of action, administration, safety considerations, side effects, and available products.
Because olaparib is a prescription anticancer medicine, treatment decisions should be based on current prescribing information and advice from qualified healthcare professionals.
The references below are selected from regulatory agencies, official medicine information, and manufacturer sources. Regulatory approvals and recommendations can differ between countries and may be updated over time.
Regulatory and Official Medicine References
U.S. Food and Drug Administration — LYNPARZA (olaparib)
The U.S. Food and Drug Administration prescribing information for LYNPARZA provides detailed information about olaparib tablets, including:
- Approved indications
- Recommended dosage
- Dose modifications
- Contraindications
- Warnings and precautions
- Adverse reactions
- Drug interactions
- Use in specific patient populations
- Pregnancy and lactation information
- Clinical studies
- Product information
The FDA prescribing information is an important reference for understanding the regulatory use of olaparib in the United States.
European Medicines Agency — Lynparza
The European Medicines Agency provides official European medicine information for Lynparza (olaparib).
The European regulatory information includes details concerning:
- Therapeutic indications
- Administration
- Safety information
- Adverse effects
- Contraindications and precautions
- Use in different cancer treatment settings
- Regulatory product information
European indications may differ from those approved by other national regulatory authorities.
DailyMed — LYNPARZA
DailyMed provides official labeling information for prescription medicines marketed in the United States.
The LYNPARZA listing provides information concerning olaparib tablets, including the available tablet strengths, prescribing information, warnings, adverse reactions, interactions, and other labeling information.
Manufacturer References
Everest Pharmaceuticals Ltd.
Everest Pharmaceuticals Ltd. is the manufacturer associated with Olanib 150 mg, an olaparib 150 mg product listed in the company’s pharmaceutical portfolio.
Manufacturer information can be useful for confirming product identity, packaging information, and product-specific verification details.
For product-specific questions about Olanib 150 mg, patients and healthcare professionals should rely on current information supplied by the manufacturer and authorized pharmaceutical channels.
Ziska Pharmaceuticals Limited
Ziska Pharmaceuticals Limited is the manufacturer associated with Olakin 150 mg, an olaparib 150 mg product listed in the company’s oncology portfolio.
Manufacturer information can help with product identification and verification of packaging or authentication information.
For questions concerning Olakin 150 mg, users should consult current information provided by Ziska Pharmaceuticals Limited or an authorized pharmaceutical source.
What Information Should Be Checked in the References?
When reviewing information about olaparib, readers should pay particular attention to:
Approved Indications
The conditions for which olaparib is approved can differ according to country, cancer type, biomarker status, previous treatment, and whether olaparib is being used alone or with another medicine.
Recommended Dosage
The prescribed dose can depend on the indication, kidney function, other medicines, adverse reactions, and other patient-specific factors.
A 150 mg tablet is a tablet strength and does not necessarily represent the complete dose prescribed for a patient.
Safety Information
Official prescribing information should be consulted for important risks, including serious blood-related disorders, pneumonitis, and embryo-fetal toxicity.
Drug Interactions
Olaparib can interact with medicines that affect its metabolism or transport. The complete prescribing information should be reviewed before starting, stopping, or changing other medicines.
Patient-Specific Considerations
Age, kidney function, pregnancy status, breastfeeding, previous cancer treatment, existing medical conditions, and concurrent medicines can affect treatment decisions.
Primary Reference Categories
For ongoing clinical use, the following source hierarchy is recommended:
- Current national regulatory prescribing information
- Official regulatory medicine information
- Official manufacturer product information
- Qualified oncology or pharmacy professionals
- Reliable peer-reviewed medical literature and clinical guidelines
Regulatory documents should take priority when there is a difference between general educational material and the current approved product labeling in the patient’s country.
Important Note About International Differences
Olaparib approvals are not necessarily identical worldwide.
An indication that is authorized by one regulatory authority may have different requirements, restrictions, combinations, or eligibility criteria in another country.
For this reason, readers should not assume that information from one country automatically applies to another.
Healthcare professionals should use the prescribing information applicable to the patient’s location.
Clinical Literature
Peer-reviewed clinical research and oncology literature may provide additional information about:
- Olaparib clinical trials
- PARP inhibition
- Homologous recombination repair
- BRCA1 and BRCA2 alterations
- Homologous recombination deficiency
- Treatment outcomes
- Safety and tolerability
- Combination treatment strategies
- Long-term clinical experience
Clinical literature should be interpreted in the context of the approved indication and the patient’s individual circumstances.
Reference Use on This Website
The references supporting Olaparib150mg.com are intended to help readers understand the medicine and locate authoritative information.
This website does not replace:
- A prescription
- An oncology consultation
- A pharmacist’s advice
- Official prescribing information
- Individualized medical assessment
Information on this website should not be used to independently diagnose cancer, select cancer treatment, change a prescribed dose, or discontinue treatment.
Product-Specific References
Olanib 150 mg
Generic Medicine: Olaparib
Brand: Olanib
Strength: 150 mg
Company: Everest Pharmaceuticals Ltd.
Product-specific information should be confirmed using current Everest Pharmaceuticals product information and verification resources.
Olakin 150 mg
Generic Medicine: Olaparib
Brand: Olakin
Strength: 150 mg
Company: Ziska Pharmaceuticals Limited
Product-specific information should be confirmed using current Ziska Pharmaceuticals product information and verification resources.
Reference Maintenance
Medical information can change as new clinical evidence becomes available and regulatory authorities update product labeling.
For this reason, references should be reviewed periodically and updated when:
- Regulatory approvals change
- Product labeling is revised
- New safety information becomes available
- New clinical evidence changes treatment recommendations
- Manufacturer product information is updated
The most current official prescribing information should always be used for clinical decision-making.
Reference Disclaimer
The inclusion of a source on this page does not mean that every statement on Olaparib150mg.com is reproduced from that source.
The website summarizes medical information for educational purposes and should not be considered a substitute for the complete official prescribing information.
Where an official regulatory document and general educational information differ, the applicable current regulatory document and advice from a qualified healthcare professional should be followed.
Key Reference Sources
U.S. Food and Drug Administration (FDA)
Official prescribing information for LYNPARZA (olaparib).
European Medicines Agency (EMA)
Official European medicine information for Lynparza (olaparib).
DailyMed
Official U.S. labeling information for LYNPARZA.
Everest Pharmaceuticals Ltd.
Manufacturer information for Olanib 150 mg and related product-verification information.
Ziska Pharmaceuticals Limited
Manufacturer information for Olakin 150 mg and related product-verification information.
Final Reminder
Olaparib is a prescription targeted cancer medicine that requires appropriate medical supervision.
Always use the most recent approved prescribing information applicable to your country and treatment setting.
For questions about whether olaparib is appropriate, what dose should be taken, how long treatment should continue, or whether it can safely be combined with another medicine, consult the treating oncologist or another qualified healthcare professional.